|
EPB41 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6251444634463E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.82200954113432E-13 |
| Normal-vs-Stage2 |
1.50500000017928E-07 |
| Normal-vs-Stage3 |
3.82693876588291E-13 |
| Normal-vs-Stage4 |
1.46429979253071E-10 |
| Stage1-vs-Stage2 |
7.869400E-01 |
| Stage1-vs-Stage3 |
5.107800E-02 |
| Stage1-vs-Stage4 |
9.234100E-02 |
| Stage2-vs-Stage3 |
2.976400E-01 |
| Stage2-vs-Stage4 |
2.811800E-01 |
| Stage3-vs-Stage4 |
8.653200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.99840144432528E-15 |
| Normal-vs-AfricanAmerican |
2.34040000002267E-06 |
| Normal-vs-Asian |
2.35529995507022E-09 |
| Caucasian-vs-AfricanAmerican |
8.972800E-01 |
| Caucasian-vs-Asian |
7.106600E-01 |
| AfricanAmerican-vs-Asian |
9.206400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.83030002265383E-09 |
| Normal-vs-Female |
4.50249837413708E-11 |
| Male-vs-Female |
6.325400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.30769950423826E-10 |
| Normal-vs-Age(41-60Yrs) |
3.99680288865056E-15 |
| Normal-vs-Age(61-80Yrs) |
2.09210426760364E-11 |
| Normal-vs-Age(81-100Yrs) |
1.422350E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.149700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.616300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.363600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.907600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.778200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.762000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.433700E-02 |
| Classical-VS-Follicular |
2.279600E-01 |
| Classical-VS-Other |
4.946000E-01 |
| Classical-VS-Normal |
1.6286971771251E-12 |
| Tall-VS-Follicular |
1.431520E-02 |
| Tall-VS-Other |
8.820200E-01 |
| Tall-VS-Normal |
2.19729789918688E-11 |
| Follicular-VS-Other |
3.394600E-01 |
| Follicular-VS-Normal |
9.30689999512069E-08 |
| Other-VS-Normal |
7.428100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.92169646651541E-11 |
| Normal-vs-N1 |
2.49789078310414E-12 |
| N0-vs-N1 |
7.938400E-02 |
|
|
